Evidence map›Paper›PMID 26544571›Full record

ArticlePLoS genetics2015

DNA Repair Cofactors ATMIN and NBS1 Are Required to Suppress T Cell Activation.

Jana Prochazkova, Shinya Sakaguchi, Michel Owusu, Abdelghani Mazouzi, Marc Wiedner, Georgia Velimezi, Martin Moder, Gleb Turchinovich, Anastasiya Hladik, Elisabeth Gurnhofer and 6 more

Open access · goldAbstract read
In one paragraph

Article in PLoS genetics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 4 institutions in 2 countries.

Jana ProchazkovaCeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.
Shinya SakaguchiDivision of Immunobiology, Institute of Immunology, Center for Pathophysiology, Infectiology and Immunology, Vienna, Austria.
Michel OwusuCeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.
Abdelghani MazouziCeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.
Marc WiednerCeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.
Georgia VelimeziCeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.
Martin ModerCeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.
Gleb TurchinovichLondon Research Institute, Cancer Research UK, London, United Kingdom.
Anastasiya HladikDepartment of Medicine I, Laboratory of Infection Biology, Medical University of Vienna, Vienna, Austria.
Elisabeth GurnhoferClinical Institute for Pathology, Medical University Vienna, Vienna, Austria.
Adrian HaydayLondon Research Institute, Cancer Research UK, London, United Kingdom.
Axel BehrensLondon Research Institute, Cancer Research UK, London, United Kingdom.
Sylvia KnappCeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.
Lukas KennerClinical Institute for Pathology, Medical University Vienna, Vienna, Austria.
Wilfried EllmeierDivision of Immunobiology, Institute of Immunology, Center for Pathophysiology, Infectiology and Immunology, Vienna, Austria.
Joanna I LoizouCeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.
Austrian Academy of Sciences · ATMedical University of Vienna · ATCancer Research UK · GBCeMM Research Center for Molecular Medicine · AT

Funding

Austrian Science Fund FWF P 23641Austrian Science Fund FWF P 24766Austrian Science Fund FWF P 26193Austrian Science Fund FWF P 27747Cancer Research UK 15679Cancer Research UK 19309
6 · The paper itself

Abstract

Proper development of the immune system is an intricate process dependent on many factors, including an intact DNA damage response. The DNA double-strand break signaling kinase ATM and its cofactor NBS1 are required during T cell development and for the maintenance of genomic stability. The role of a second ATM cofactor, ATMIN (also known as ASCIZ) in T cells is much less clear, and whether ATMIN and NBS1 function in synergy in T cells is unknown. Here, we investigate the roles of ATMIN and NBS1, either alone or in combination, using murine models. We show loss of NBS1 led to a developmental block at the double-positive stage of T cell development, as well as reduced TCRα recombination, that was unexpectedly neither exacerbated nor alleviated by concomitant loss of ATMIN. In contrast, loss of both ATMIN and NBS1 enhanced DNA damage that drove spontaneous peripheral T cell hyperactivation, proliferation as well as excessive production of proinflammatory cytokines and chemokines, leading to a highly inflammatory environment. Intriguingly, the disease causing T cells were largely proficient for both ATMIN and NBS1. In vivo this resulted in severe intestinal inflammation, colitis and premature death. Our findings reveal a novel model for an intestinal bowel disease phenotype that occurs upon combined loss of the DNA repair cofactors ATMIN and NBS1.

Indexed as

DNA RepairAnimalsCell Cycle ProteinsColitisDNA-Binding ProteinsDNA DamageImmunophenotypingLymphocyte ActivationMiceNuclear ProteinsReactive Oxygen SpeciesReceptors, Antigen, T-Cell, alpha-betaRecombination, GeneticSpleenT-LymphocytesTranscription FactorsATMIN protein, mouseCell Cycle ProteinsDNA-Binding ProteinsNijmegen breakage syndrome 1 protein, mouseNuclear ProteinsReactive Oxygen SpeciesReceptors, Antigen, T-Cell, alpha-betaTranscription Factors

Identifiers

PMID26544571
PMCPMC4636180
OpenAlexW2171132356

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.